Industry Challenges and Strategic Opportunities

6.2 M+ Helicobacter pylori (HP) Infection

Large affected population with significant gastrointestinal health needs

2.1 M+Functional Digestive Disorders (FD)

A growing population affected by long-term digestive discomfort

Traditional Antibiotic Challenges

Over 620 million people in China are affected by H. pylori (HP), while more than 210 million experience functional digestive disorders (FD). Rising antibiotic resistance and microbiome disruption continue to drive demand for safer gastrointestinal health solutions.

Demand for High-Activity Microbiome Solutions

Most current “anti-HP” products rely on short-term microbial suppression with limited microbiome support. The market is increasingly seeking high-activity probiotic solutions designed to support gastric microbial balance and gastrointestinal health.

Source: Clinical Study on the Stomach-Derived Strain Lactobacillus plantarum LPF-01 in Gastric Health Applications